Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis

NCT06718933 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Metastatic
Breast Cancer Brain Metastases

Interventions

DRUG: SHR-A1811
DRUG: Bevacizumab
DRUG: Pyrotinib

Sponsor

Fudan University